CY1119725T1 - Ημιστερεη υδατικη φαρμακευτικη συνθεση που περιεχει ταπενταδολη - Google Patents

Ημιστερεη υδατικη φαρμακευτικη συνθεση που περιεχει ταπενταδολη

Info

Publication number
CY1119725T1
CY1119725T1 CY20181100006T CY181100006T CY1119725T1 CY 1119725 T1 CY1119725 T1 CY 1119725T1 CY 20181100006 T CY20181100006 T CY 20181100006T CY 181100006 T CY181100006 T CY 181100006T CY 1119725 T1 CY1119725 T1 CY 1119725T1
Authority
CY
Cyprus
Prior art keywords
semi
composition containing
drug composition
solid aqueous
aqueous drug
Prior art date
Application number
CY20181100006T
Other languages
Greek (el)
English (en)
Inventor
Ulrich Reinhold
Marc Schiller
Eva WULSTEN
Sabine Karine Katrien INGHELBRECHT
Roger Carolus Augusta Embrechts
Ulrich Feil
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1119725T1 publication Critical patent/CY1119725T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CY20181100006T 2011-03-04 2018-01-03 Ημιστερεη υδατικη φαρμακευτικη συνθεση που περιεχει ταπενταδολη CY1119725T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
EP11003603 2011-05-03
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol
EP12710026.1A EP2680834B1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Publications (1)

Publication Number Publication Date
CY1119725T1 true CY1119725T1 (el) 2018-06-27

Family

ID=44652117

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100006T CY1119725T1 (el) 2011-03-04 2018-01-03 Ημιστερεη υδατικη φαρμακευτικη συνθεση που περιεχει ταπενταδολη

Country Status (24)

Country Link
US (3) US9446008B2 (https=)
EP (3) EP2680834B1 (https=)
JP (3) JP6027549B2 (https=)
KR (2) KR102039320B1 (https=)
CN (1) CN103501774A (https=)
AU (2) AU2012224954C1 (https=)
BR (1) BR112013022556A8 (https=)
CA (1) CA2828637C (https=)
CY (1) CY1119725T1 (https=)
DK (1) DK2680834T3 (https=)
EA (2) EA025194B1 (https=)
ES (2) ES2654407T3 (https=)
HR (1) HRP20171836T1 (https=)
HU (1) HUE037491T2 (https=)
IL (2) IL227826B (https=)
LT (1) LT2680834T (https=)
MX (2) MX374468B (https=)
NO (1) NO2680834T3 (https=)
PL (1) PL2680834T3 (https=)
PT (2) PT2680834T (https=)
RS (1) RS56692B1 (https=)
SI (1) SI2680834T1 (https=)
WO (1) WO2012119729A1 (https=)
ZA (1) ZA201306480B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101946790B1 (ko) 2011-03-04 2019-02-13 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
RS56692B1 (sr) * 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
WO2015014980A1 (en) * 2013-08-02 2015-02-05 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
EP3273953B1 (en) 2015-03-27 2019-01-02 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
CN109996533A (zh) 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
JP2021532112A (ja) * 2018-07-24 2021-11-25 ドクトア・アウグスト・ボルフ・ゲーエムベーハー・ウント・コンパニー・カー・ゲー−アルツナイミツテル 抗コリン性化合物の局所用エマルション
EP3846852A4 (en) 2018-09-07 2022-06-15 R.P. Scherer Technologies, LLC Solid or semisolid lipid based dosage form stabilization through curing and addition of low hlb surfactant(s)
EP3941422A4 (en) 2019-03-18 2023-04-19 Sunstar Americas, Inc. ORAL CARE COMPOSITION

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス, インコーポレイテッド 内蔵痛症候群を処置するためのneおよび5−ht再取り込み阻害剤
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
EP1545477A4 (en) 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
WO2005112926A1 (en) 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
DE602004007905T2 (de) 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
BRPI0513300B1 (pt) 2004-07-01 2018-11-06 Gruenenthal Gmbh forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol
CN101208081A (zh) 2005-04-28 2008-06-25 谢拉奎斯特生物科学有限公司 治疗疼痛的方法和组合物
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
RU2442576C2 (ru) 2006-04-28 2012-02-20 Грюненталь Гмбх Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
CN105561311B (zh) 2006-04-28 2019-07-16 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
WO2008012283A1 (en) 2006-07-24 2008-01-31 Janssen Pharmaceutica Nv Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
CN102908339A (zh) * 2007-11-23 2013-02-06 格吕伦塔尔有限公司 他喷他多组合物
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
BRPI0921725A2 (pt) 2008-10-30 2016-01-05 Grüenthal GmbH formas de dosagem potentes do tapentadol
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
EP2552486B1 (en) * 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
RS56692B1 (sr) 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol

Also Published As

Publication number Publication date
EA201600442A1 (ru) 2017-02-28
KR101911362B1 (ko) 2018-10-25
EP3766489A1 (en) 2021-01-20
CA2828637C (en) 2019-06-11
CA2828637A1 (en) 2012-09-13
ES2654407T3 (es) 2018-02-13
ZA201306480B (en) 2014-05-28
IL227826A0 (en) 2013-09-30
US20180133174A1 (en) 2018-05-17
JP6259042B2 (ja) 2018-01-10
JP2014506900A (ja) 2014-03-20
AU2012224954B2 (en) 2016-10-20
SI2680834T1 (en) 2018-01-31
EA033171B1 (ru) 2019-09-30
PL2680834T3 (pl) 2018-03-30
PT3766489T (pt) 2022-04-07
EP3766489B1 (en) 2022-03-16
HRP20171836T1 (hr) 2017-12-29
AU2012224954C1 (en) 2017-04-06
MX344473B (es) 2016-12-16
DK2680834T3 (en) 2017-12-04
LT2680834T (lt) 2018-01-10
BR112013022556A2 (pt) 2016-12-06
MX2013010100A (es) 2013-10-01
US20160346229A1 (en) 2016-12-01
IL258357A (en) 2018-05-31
EP3290029A1 (en) 2018-03-07
KR20140013020A (ko) 2014-02-04
MX374468B (es) 2025-03-06
IL227826B (en) 2018-04-30
PT2680834T (pt) 2018-01-25
WO2012119729A1 (en) 2012-09-13
ES2910085T3 (es) 2022-05-11
US9446008B2 (en) 2016-09-20
CN103501774A (zh) 2014-01-08
US20120225950A1 (en) 2012-09-06
NO2680834T3 (https=) 2018-03-17
EP3290029B1 (en) 2020-09-02
KR20180116463A (ko) 2018-10-24
JP2017039756A (ja) 2017-02-23
EP2680834B1 (en) 2017-10-18
JP2018065839A (ja) 2018-04-26
EA025194B1 (ru) 2016-11-30
KR102039320B1 (ko) 2019-11-01
EA201300988A1 (ru) 2014-06-30
BR112013022556A8 (pt) 2018-01-16
EP2680834A1 (en) 2014-01-08
HUE037491T2 (hu) 2018-09-28
JP6027549B2 (ja) 2016-11-16
RS56692B1 (sr) 2018-03-30
AU2012224954A1 (en) 2013-09-19
JP6670283B2 (ja) 2020-03-18
AU2017200040B2 (en) 2018-09-06
AU2017200040A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
CY1119725T1 (el) Ημιστερεη υδατικη φαρμακευτικη συνθεση που περιεχει ταπενταδολη
CY1123023T1 (el) Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1115043T1 (el) Φαρμακευτικο σκευασμα
BR112015014502A2 (pt) composições para higiene oral contendo haletos de zinco-aminoácidos
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
BR112015004936A2 (pt) composição farmacêutica revestida contendo regorafenib
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
CY1120094T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει despr036 eξenδinh-4(1-39)-lys6-nh2 για χρηση στην θεραπευτικη αγωγη μιας νευροεκφυλιστικης ασθενειας
CY1117426T1 (el) Παρεντερικη χορηγηση ταπενταδολης
CY1119446T1 (el) Φαρμακοτεχνικες μορφες δαρουναβιρης
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
EA201500245A1 (ru) Твердый фармацевтический препарат, который содержит левотироксин
CY1118074T1 (el) Ανθελονοσιακοι παραγοντες
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
CY1118585T1 (el) Ενωση βενζοθειαζολονης
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
BR112015009839A2 (pt) composição farmacêutica de tapentadol para administração parenteral
EP2898912A4 (en) Drug administration instrument
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид